New drug cocktail aims to boost lung cancer surgery success

NCT ID NCT07642024

Recruiting now Disease control Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Aug 04, 2026 · Updated 3 times

Summary

This study tests whether adding a new drug called BL-B01D1 to the standard targeted therapy osimertinib can improve outcomes for people with a specific type of lung cancer (EGFR-mutated non-small cell lung cancer) that can be removed with surgery. About 90 participants will receive the drug combination before and after surgery. The main goal is to see if the tumor shrinks significantly or disappears by the time of surgery.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: BL-B01D1 (izalontamab brengitecan) combined with osimertinib
What this could lead to: If successful, this combination could become a new standard perioperative therapy to improve outcomes for patients with EGFR-mutated lung cancer.
What could go wrong: This is an early-to-mid-stage trial with only 90 participants. The combination may cause significant side effects, and results may not generalize to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EGFR-MUTATED RESECTABLE NON-SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-SMALL CELL LUNG CANCER

Contacts and locations

Locations

Shanghai East Hospital
RECRUITING

Shanghai, Shanghai Municipality, China
Shanghai Pulmonary Hospital
RECRUITING

Shanghai, Shanghai Municipality, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.